Screening of anti-heart failure active compounds from fangjihuangqi decoction in verapamil-induced zebrafish model by anti-heart failure index approach

Jun Li1†, Yue Zhu1†, Xiaoping Zhao2*, Lu Zhao1,3, Yi Wang1,3,4,5 and Zhenzhong Yang1,3,4,5*

1Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China, 2School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, 3Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, China, 4Jinhua Institute of Zhejiang University, Jinhua, China, 5Innovation Center in Zhejiang University, State Key Laboratory of Component-Based Chinese Medicine, Hangzhou, China

Heart failure is the end stage of various cardiovascular diseases. Fangjihuangqi Decoction (FJHQD) is a famous traditional Chinese medicine (TCM) formula, which is clinically effective in the treatment of chronic heart failure. However, the anti-heart failure ingredients of FJHQD have not been clarified, and the related mechanisms of action are rarely studied. In the present study, through quantification analysis of heart rate and ventricular area changes, a heart failure model and cardiac function evaluation system in cardiomyocytes-labelled Tg (cmlc2: eGFP) transgenic zebrafish larvae were constructed, and the anti-heart failure index (AHFI) that can comprehensively evaluate the cardiac function of zebrafish was proposed. Based on this model, FJHQD, its mainly botanical drugs, components and ingredients were evaluated for the anti-heart failure effects. The results showed that FJHQD and its botanical drugs exhibited potent anti-heart failure activity. Furthermore, total alkaloids from Stephania tetrandra S. Moore, total flavonoids from Astragalus mongholicus Bunge and total flavonoids from Glycyrrhiza uralensis Fisch. ex DC. were identified to be the main components exerting the anti-heart failure activity of FJHQD. Then, we screened the main ingredients of these components, and glycyrrhizic acid,
Introduction

Cardiovascular disease (CVD) is one of the leading causes of death all over the world, responsible for about 9.6 million deaths per year among men and 8.9 million women, accounting for about one-third of all deaths from diseases, while China has the highest number of CVD deaths (Roth et al., 2020). Heart failure is a clinical syndrome characterized by fatigue and dyspnea caused by left (or systemic) ventricular dysfunction, often with signs of congestion (Rossignol et al., 2019; McDonagh et al., 2021), which is the terminal stage of various cardiovascular diseases. Conventional pharmacological treatment for heart failure includes angiotensin converting enzyme inhibitors (ACEIs), β-blockers, diuretics, corticosteroid receptor antagonists, sodium-glucose cotransporter two inhibitors and so on (Gupta et al., 2018). Despite numerous drugs available, the morbidity and mortality of heart failure remain high (Rossignol et al., 2019). Therefore, how to effectively mitigate disease progression and reduce the morbidity and mortality of heart failure has become a global public health problem.

Traditional Chinese medicine (TCM) provides rich resources for its unique biological ingredients预防和治疗多种疾病. FJHQD, an herbal formula contains Glycyrrhiza uralensis, Atractylodis Macrocephalae Rhizoma] (AMR), and [Stephania tetrandra (STR), Astragalus mongholicus Bunge [Fabaceae; Astragali Radix] (AR), Atractylodes macrocephala Koidz [Asteraceae; Atractylodis Macrocephalae Rhizoma] (AMR), and Glycyrrhiza uralensis Fisch. ex DC [Fabaceae; Glycyrrhizae Radix et Rhizoma] (GRR), which is prescribed to treat chronic heart failure, chronic glomerulonephritis, cardiogenic edema, and rheumatoid arthritis embolism (Zhang et al., 2019; Hwa et al., 2021). However, due to the complicated composition in naturally derived materials, how FJHQD and its active ingredients prevent heart failure is still largely unclear.

Zebrafish is a model organism with powerful advantages making it particularly attractive for biomedical researchers. As an experimental vertebrate, zebrafish is more relevant to human than the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster, but of relatively lower cost, smaller size and rapid development compared with the murine model Mus musculus (Giacomotto and Segalat, 2010). The heart initiates heartbeat from 24 h postfertilization (hpf), and is fully formed by 48 hpf. Additionally, the embryos and larvae are nearly transparent, making it possible to observe the internal structures, such as heart, in real time without invasive instrumentation. Zebrafish has been used as a model organism for cardiovascular toxicity or activity screening (Bourne and Beis, 2016). Several chemical-induced heart failure models in zebrafish have been reported (Shi et al., 2018; Zhu et al., 2018). In this study, we aim to establish the verapamil-induced heart failure model in zebrafish larvae and use it for the evaluation of the anti-heart failure activity of FJHQD and its active ingredients screening. The therapeutic mechanisms of FJHQD and its active ingredients were also explored.

Materials and methods

Chemicals and reagents

AR was collected from the Inner Mongolia Autonomous Region, China. AMR and STR were collected from Zhejiang Province, China. GRR was collected from the Xinjiang Uygur Autonomous Region, China. Zingiber officinale Roscoe [Zingiberaceae; Zingiberis Rhizoma Recens] (ZRR) was collected from Yunnan Province, China. Ziziphus jujuba Mill [Rhamnaceae; Jujubae Fructus] (JF) was collected from Hebei Province, China. Voucher specimens were deposited in Pharmaceutical Informatics Institute, Zhejiang University, and morphologically identified by Dr. Zhenzhong Yang.

Licochalcone A, fangchinoline, tetrandrine, liquiritin apioside, isoliquiritin apioside, calycosin, formononetin, ononin, glycyrrhetinic acid and isoliquiritin were obtained from Shanghai Yuanye Biotechnology Co., Ltd. Shanghai, China. Calycosin-7-O-glucoside, liquiritin, liquiritin apioside and isoliquiritin were purchased from Shanghai Ronghe Pharmaceutical Technology Development Co., Ltd. (Shanghai, China). Licochalcone B and glycyrrhizinic acid were purchased from Chengdu Must Bio-Technology Co., Ltd (Chengdu, China). The purity of all reference standards was more than 97%. Verapamil and DCFH-DA were obtained from Chengdu Must Bio-Technology Co., Ltd (Chengdu, China). The purity of all reference standards was more than 97%. Verapamil and DCFH-DA were obtained...
from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). N-Phenylthiourea (PTU) was purchased from Sigma-Aldrich (St. Louis, MO, United States). Dimethyl sulfoxide (DMSO) was obtained from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).

Sample preparation

FJHQD extract preparation: The preparation of FJHQD extract has been reported in our previous study (Yang et al., 2022). STR, AR, AMR, GRR, ZRR and JF were mixed at a ratio of 60:75:45:30:45:36, and then extracted twice with water (1:8, m/V) for 1 h under reflux. The extract was combined and concentrated under 70°C and the reduced pressure to dry, and then re-suspended in DMSO at a concentration of 500 mg/ml.

Extracts preparation of botanical drug: The preparation process is similar with FJHQD. The individual botanical drug was extracted twice with water (1:8, m/V) for 1 h under reflux. The extract was combined and concentrated under 70°C and the reduced pressure to dry, and then re-suspended in DMSO at a concentration of 500 mg/ml.

Main components preparation: Herbal extracts were loaded onto the macroporous resin, eluted with water and ethanol solutions of different concentrations. The eluates containing the corresponding components were collected, combined, and concentrated to dry. The components were stored for the further experiments.

Zebrafish husbandry

Wildtype AB strain and Tg(cmlc2: eGFP) (Kwan et al., 2007) transgenic zebrafish were all obtained from the Laboratory Animal Center of Zhejiang University. Zebrafish were maintained following standard protocols. E3 medium (0.29 g/L NaCl, 0.013 g/L KCl, 0.048 g/L CaCl₂·2H₂O, 0.082 g/L MgCl₂·6H₂O, pH 7.2) was used as the zebrafish medium. Embryos were obtained through natural spawning.

Zebrafish embryo collection and sample treatment

Adult zebrafish were used to generate zebrafish embryos. Fertilized embryos were selected by microscopic examination and then raised in embryo medium containing PTU (0.2 mM) at 28°C for 2 days. Zebrafish larvae of 3 days post fertilization (dpf) were collected into a 12-well microplate (12–15 fish per well), and were treated with FJHQD for another 4 h. DMSO (0.2% v/v final concentration) was used as negative control. At the 76 hpf stage, the larvae were washed three times with fish water, and treated with verapamil (200 µM) for 30 min. After verapamil treatment, the larvae were anesthetized and transferred into 96-well microplate (one fish per well), and images were acquired under Leica DMI 3000 B inversed microscope system (Leica Microsystems Inc., United States).

Image analysis-based quantitative phenotyping of cardiac functions in zebrafish.

Heart rate (HR), fractional area change (FAC), stroke volume (SV), ejection fraction (EF) and cardiac output (CO) were selected as indicators of cardiac function (Ho et al., 2007; Shin et al., 2010). In order to accurately assess the cardiac function in zebrafish, we calculated the HR and selected frames at the end systole (ES) phase and end diastole (ED) phase from the sequence images. With the endocardium bounded, the heart is defined, and its area, as well as the long and short axis, was measured. The indicators of cardiac function were calculated via the following formulae:

\[ \text{FAC} = \frac{\text{EDA} - \text{ESA}}{\text{EDA}} \times 100\% \]

\[ \text{EDA}: \text{the heart area of ED}; \text{ESA}: \text{the heart area of ES}. \]

\[ \text{FS} = \frac{D_L - D_s}{D_s} \times 100\% \]

\[ \text{FS}: \text{fractional shortening}; \text{D}_L, \text{D}_s: \text{the length of long and short axis}. \]
The Ventricular volume = 4/3 × π × 1/2 a × 1/4 b^2

a and b are the half-long and half-short axis of heart, respectively.

SV = EDV − ESV

EDV: the ventricular volume of ED; ESV: the ventricular volume of ES.

EF = SV / EDV × 100%

EDV: the ventricular volume of ED.

CO = SV × HR

Reactive oxygen species measurement

Zebrafish larvae were incubated with 10 μM of DCFH-DA solution for 30 min at 28.5°C in the dark. After that, larvae were washed with E3 medium and imaged with Leica DMI 3000 B. The fluorescence intensity of individual larvae was quantified using the ImageJ program (v1.8.0).

HPLC analysis

According to the method of our previous research, we performed HPLC analysis of the components of FJHQD (Yang et al., 2022). In brief, chromatographic separations were carried out at 30°C on a CORTECS C18 column (4.6 mm × 100 mm, 2.7 mm) with acidified water (0.1% formic acid) and acetonitrile as mobile phases A and B, respectively. The solvent gradient adopted was as follows: 0 min, 2%B; 4 min, 5%B; 10 min, 12%B; 15 min, 15%B; 20 min, 20% B; 25 min, 25% B; 30 min, 33%B; 35 min, 45%B; 45 min, 70% B; 50 min, 100%B. The flow rate was 0.7 ml/min, the detection wavelength was 254 nm, and the injection volume was 5 μL.

mRNA extraction and qPCR

Zebrafish larvae were transferred to 6-well plates with 30 larvae per well, and total RNA was extracted using the RNA Rapid Extraction Kit, followed by reverse transcription into single-stranded cDNA using the HiFiScript cDNA Synthesis Kit (ES Science). cDNA was stored at -20°C. Fluorescent quantitative PCR was performed using 2 × SYBR Green qPCR Mater Mix (Bimake). Primer sequences are shown in Table 1.
Anti-heart failure index calculation

The data normalization method is given below using HR as an example.

\[
B_{HR,i} = \frac{HR_i}{HR_{ctrl}}
\]

\(HR_i\): heart rate of ingredient \(i\) treated group; \(HR_{ctrl}\): heart rate of the control group. The data normalization method of the rest cardiac function indicators is calculated in a similar way to HR.

The formula for calculating the recovery score of cardiac function (RCF) is given below using HR as an example.

\[
RCF_{HR,i} = \frac{B_{HR,i} - B_{HR,m}}{1 - B_{HR,m}} 	imes 100\%
\]

\(RCF_{HR,i}\): recovery score of ingredient \(i\) in HR; \(B_{HR,i}\): normalized HR of ingredient \(i\) treated group; \(B_{HR,m}\): normalized HR of verapamil-induced group. The recovery scores of the rest cardiac function indicators are calculated in a similar way to heart rate.

Considering the correlation of the cardiac function indicators, four relatively independent recovery scores of HR, EF, CO and FAC, were selected for the calculation of the anti-heart failure index (AHFI), which was calculated as follows:

\[AHFI_i = RCF_{HR,i} + RCF_{EF,i} + RCF_{CO,i} + RCF_{FAC,i}\]

\(AHFI_i\): anti-heart failure index of ingredient \(i\); \(RCF_{HR,i}\): heart rate recovery score of ingredient \(i\); \(RCF_{EF,i}\): ejection fraction recovery score of ingredient \(i\); \(RCF_{CO,i}\): cardiac output recovery score of ingredient \(i\); \(RCF_{FAC,i}\): fractional area change recovery score of ingredient \(i\).

Statistics

All data are presented as the mean ± standard deviation (SD). Differences between two groups were analyzed using the two-tailed Student’s t-test. Multiple group comparison was performed by one-way ANOVA. The \(p\) value < 0.05 was considered statistically significant.
Results

Verapamil-induced heart failure model in zebrafish

As previously reported, verapamil leads to decreased cardiac function and venous stasis in zebrafish larvae, which is largely consistent with the symptoms of heart failure in humans. Therefore, we chose verapamil to build a heart failure model with cardiomyocytes-labelled Tg(cmlc2; eGFP) transgenic zebrafish larvae (Zhu et al., 2018; Li et al., 2021). Verapamil at the concentration of 200 µM was adopted to treat zebrafish larvae at 76 hpf for 30 min (Figure 1A). Then, under the microscope, it can be observed that the zebrafish heart rate generally slowed down (Figure 1C) and the contractile ability of the heart was obviously weakened (Figure 1B). After analyzing the sequence images of zebrafish heart, the parameters indicating the contractile function, i.e., FAC, EF, FS, SV and CO, were significantly reduced in the verapamil-treated group (Figures 1B–H). In this model, the heart rate and cardiac output reduced, which depicted the zebrafish heart failure model was developed (Zhu et al., 2018). Thus, we continued to examine the efficacy of FJHQD, its botanical drugs, components and ingredients on this model.

FJHQD alleviates cardiac function in verapamil-induced heart failure model

Toxicity analysis suggested that within a range of 10 µg/ml to 250 µg/ml, FJHQD incubation from 72 to 76 hpf showed no significant pericardial edema, bradycardia or death on the survival or general development of zebrafish larvae, so the maximum concentration for subsequent studies was set to be 250 µg/ml. Next, we added the FJHQD treatment before verapamil stimulation, and evaluated its effects on cardiac function (Figures 2A,B). Through quantification analysis of zebrafish ventricular area by fluorescent sequence imaging, a significant restoration of cardiac function was observed in the larvae protected by FJHQD in a dose-dependent manner, with 250 µg/ml concentration providing the best rescue effects (Figures 2C–H).
The therapeutic effects of botanical drugs on verapamil-induced heart failure model in zebrafish

FJHQD is a famous TCM formula mainly composed of STR, AR, AMR and GRR, which is clinically effective in the treatment of chronic heart failure. To investigate the botanical drugs in FJHQD that exert anti-heart failure activity, the extracts of individual botanical drug were prepared and evaluated for their anti-heart failure effects in the zebrafish heart failure model. Markedly, compared with model group, GRR treatment could improve all cardiac function indicators in zebrafish. Moreover, STR and AR also exhibited remarkable anti-heart failure activity in most cardiac function indicators (Figures 3B–G). These results suggested that STR, AR and GRR may be the botanical drugs that contribute the anti-heart failure activity of FJHQD.

Many studies have demonstrated the accumulation of ROS in the cardiovascular system is a response to various stresses and heart failure (Giordano, 2005; D’Aiuto et al., 2010; Bondia-Pons et al., 2012; Liu et al., 2016; Ojha et al., 2016; Singh et al., 2016; van der Pol et al., 2019). In addition, antioxidants can ameliorate ROS-mediated cardiac abnormalities (Takimoto and Kass, 2007). In zebrafish treated with verapamil, endogenous ROS production was significantly higher than in the control group. After pretreatment with FJHQD, STR or GRR, ROS was significantly reduced compared to the model group, but not with AR. This suggested that the anti-heart failure activity of FJHQD and GRR may be, at least partly, achieved by reducing ROS production (Figures 4A,B).

The therapeutic effects of the main components of botanical drugs on verapamil-induced heart failure model in zebrafish.

In order to further search for components that exert anti-heart failure activity, the main components of extract of botanical drug were prepared, and evaluated for their anti-heart failure activity in the zebrafish model. The main components from STR include total polysaccharides of STR (P-STR) and total alkaloids.
of STR (A-STR). A-STR with the concentration of 100 μg/ml could significantly alleviate the decline in cardiac function caused by verapamil in zebrafish, while P-STR showed no obvious effect (Figure 5A). The main components from AR include total polysaccharides of AR (P-AR), total saponins of AR (S-AR), and total flavonoids of AR (F-AR). F-AR could dose-dependently alleviate most cardiac function indicators, including FAC, EF and SV, while S-AR and P-AR did not exhibit anti-heart failure activity (Figure 5B). The main components from GRR include total polysaccharides of GRR (P-GRR), total flavonoids of GRR (F-GRR), and saponins (mainly including glycyrrhizic acid and glycyrrhetinic acid). Interestingly, F-GRR showed dose-dependent therapeutic effects on all cardiac function indicators, while P-GRR didn’t exhibit anti-heart failure activity (Figure 5C). The anti-heart failure activities of glycyrrhetinic acid and glycyrrhizinic acid were evaluated separately along with other ingredients.

Characterization of chemical ingredients in the main active components of FJHQD

The chemical ingredients in A-STR, F-AR and F-GRR were analyzed using HPLC. The main chemical ingredients in A-STR were tetrandrine and fangchinoline (Supplementary Figure S1) (Tsutsumi et al., 2003; Sim et al., 2015; Xiao et al., 2018). Calycosin, calycosin-7-O-glucoside, ononin and formononetin were the main ingredients in F-AR (Supplementary Figure S2) (Su et al., 2021). The main chemical ingredients in F-GRR included liquiritigenin, liquiritin, isoliquiritigenin, isoliquiritin, liquiritin apioside, isoliquiritin apioside, licochalcone A and licochalcone B (Supplementary Figure S3) (Wang et al., 2012; Wang et al., 2020). The above results were consistent with our previous identification of the chemical ingredients in FJHQD (Yang et al., 2022), and these ingredients were selected for further study.

The therapeutic effects of main ingredients in active components on verapamil-induced heart failure model in zebrafish.

We continued to screen for the active ingredients with anti-heart failure effects in the zebrafish heart failure model. The results showed that tetrandrine (100 μM), glycyrrhizic acid (100 μM), licochalcone A (1 μM), licochalcone B (50 μM) and glycyrrizin (50 μM) could restore various cardiac function indicators to a certain extent (Figures 6A–F). However, some of the ingredients showed different alleviating effects in different cardiac function indicators, making it difficult to
compare the anti-heart failure activity between them. AHFI was proposed herein to comprehensively evaluate the anti-heart failure activity of each ingredient, and its calculation was illustrated in Materials and Methods. The AHFI of the positive drug digoxin (10 μM) was about 0.7. Glycyrrhizic acid (100 μM), licochalcone A (1 μM) and calycosin (50 μM) showed excellent anti-heart failure activities with AHFI ≥1.0, while tetrandrine (100 μM), licochalcone B (50 μM) and calycosin-7-glycoside (50 μM) also had a certain degree of anti-heart failure activities (AHFI ≥0.6). These ingredients may be the main active compounds responsible for the anti-heart failure activity of FJHQD. Notably, among these ingredients, the anti-heart failure activities of licochalcone A and licochalcone B were firstly reported. In addition, the negative value of isoliquiritigenin (AHFI < -0.5) was also noteworthy. We comprehensively
analyzed all six cardiac function indicators of isoliquiritigenin group, and found that five of them were close to those in model group, while the HR values were much lower. The HR reduced effect is one of the pharmacological effects of β-blockers, a currently used therapeutic drug for heart failure (Gupta et al., 2014). Further studies were needed to investigate the exact effect of isoliquiritigenin against heart failure.

FJHQD and its active ingredients showed regulatory effects on oxidative stress, inflammatory response and apoptosis.

In the heart, excess ROS can lead to maladaptive myocardial remodeling and progression of heart failure. ROS directly impair the electrophysiology and contractile mechanisms of cardiomyocytes by modifying core proteins of excitation-contraction coupling, including L-type calcium channels, sodium channels, potassium channels, and sodium-calcium exchangers (Takimoto and Kass, 2007; van der Pol et al., 2019). To further investigate whether the above-mentioned active ingredients against heart failure could reduce ROS content in zebrafish, the ROS fluorescent probe was photographed after co-incubation with verapamil for 30 min with zebrafish after 4 h of sample pre-treatment, and the fluorescent area was statistically analyzed. The results showed that glycyrrhizic acid (100 μM), licochalcone A (1 μM) and calycosin (50 μM) could significantly reduce the ROS elevation in zebrafish caused by verapamil. Among them, glycyrrhizic acid, licochalcone A and calycosin treatment group were even lower than the control group, showing their powerful antioxidant activities (Figure 7), which is consistent with previous reports (Haleagrahara et al., 2011; Liu et al., 2016; Ojha et al., 2016; Huang et al., 2019). The above results suggested that glycyrrhizic acid, licochalcone A and calycosin can scavenge endogenous ROS in zebrafish, or improve the anti-oxidant capacity of zebrafish.

Excessive accumulation of ROS during the development of heart failure leads to an inflammatory response and apoptosis. In order to further investigate the mechanisms of anti-heart failure effect of FJHQD, glycyrrhizic acid, licochalcone A and calycosin, the genes of heart failure markers and pro-inflammatory factors were investigated by qPCR. As results, the transcript levels of zebrafish inflammatory factors *tnfa, il1b* and *il6* were all significantly increased after verapamil treatment and can be down-regulated by FJHQD, glycyrrhizic acid and licochalcone A. In addition, the expression of heart failure markers *nppa*, the caspase family of pro-inflammatory and apoptotic factors *caspase*...
and caspase 3 also got a reduction after the treatment (Figure 8). These suggested that FJHQD and its active ingredients may exert anti-heart failure activity through pathways related to inflammation and apoptosis (Figure 9).

**Discussion**

In recent years, the clinical application of FJQHD has focused on the treatment of chronic heart failure. Although FJHQD has a great therapeutic effect on heart failure, its main ingredients and mechanisms of action are still not clear. In our study, the anti-heart failure activities of FJHQD, its main botanical drugs, components and ingredients were evaluated by verapamil-induced zebrafish heart failure model.

Heart failure is a complex group of clinical syndromes caused by multiple causes of structural abnormalities and/or dysfunctions of the heart that impair the pumping function of the heart and cannot meet the metabolic needs of the body (Rossignol et al., 2019; McDonagh et al., 2021). Oxidative stress, inflammatory response and apoptosis play important roles in the development of heart failure and they interact with each other. Oxidative stress-induced ROS accumulation is thought to be a critical process in the activation of inflammatory signaling pathways. On the other hand, inflammatory responses produce more ROS, which exacerbates oxidative stress (D’Aiuto et al., 2010; Bondia-Pons et al., 2012). Our results demonstrated that FJHQD and its active ingredients can reduce ROS levels in zebrafish. Systemic inflammation has been suggested to be a common pathobiological feature of heart failure. The pro-inflammatory cytokines TNFα, IL-1β and IL-6 are all involved in the inflammatory response related to the pathogenesis of heart failure. Previous studies reported that inhibition of transcription and translation of inflammatory factors was accompanied by an improvement in cardiac function along with a decrease in plasma levels of inflammatory factors in heart failure patients (Mann, 2015). In contrast, multiple cells of the heart can secrete pro-inflammatory cytokines, leading to left ventricular dysfunction, myocardial apoptosis, and ventricular remodeling (Parrillo et al., 1989; Skudicky et al., 2000; Sliwa et al., 2002). Previous studies found that verapamil induction in zebrafish larvae elevated the levels of ROS and malondialdehyde, decreased superoxide dismutase levels, and increased the expression of il1b, nf-kb, and tnfα (Li et al., 2021). Our results indicated that FJHQD and the active ingredients can reduce the elevated ROS and transcript levels of inflammatory factor caused by verapamil, and we speculated that they may inhibit il1b, il6, and tnfα by suppressing oxidative stress in verapamil-treated zebrafish larval model.

**FIGURE 8**
The mRNA relative expression of nppa, tnfα, il1b, il6, caspase 1 and caspase 3. N = 3. *p < 0.05 vs. Control. **p < 0.01 vs. Control, *p < 0.05 vs. Model, **p < 0.01 vs. Model.
Excess secretion of inflammatory factors can further activate caspase family proteins and subsequently initiate the apoptotic cascade response (Abbate et al., 2008). Caspase 3 is considered to be the most important effector in the apoptosis cascade, and inhibition of caspase 3 activation protects cardiomyocytes from ischemia or hypoxia-induced apoptosis in vivo and in vitro (Zhang et al., 2015). Caspase 1 is the core of the pro-inflammatory proteins in the caspase family, but it has also been found that caspase 1 can induce apoptosis of cardiomyocytes by activating caspase 3 and caspase 9 (Merkle et al., 2007). Our results showed that verapamil caused overexpression of inflammatory factors, followed by activation of the apoptotic program in cardiomyocytes and a significant increase in the mRNA expression of caspase 1 and caspase 3. However, the transcript levels of caspase 1 and caspase 3 were significantly reduced after pre-protection with FJHQD and its active ingredients.

Taken together, FJHQD can dose-dependently alleviate the decline of cardiac function caused by verapamil. STR, AR and GRR, as well as the components of A-STR, F-AR and F-GRR also had excellent anti-heart failure activity. Glycyrrhizic acid, licochalcone A and calycosin were the main ingredients of FJHQD that exhibit anti-heart failure activity. FJHQD and its active ingredients could significantly reduce the transcript levels of heart failure markers nppa, pro-inflammatory factors il1b, il6, tnfα, and the caspase family caspase 1, caspase 3, suggesting that FJHQD and its active ingredients may improve verapamil-induced decline in zebrafish cardiac function by regulating oxidative stress, inflammatory response and apoptosis-related pathways. Our study provides biological evidences toward the clinical efficacy in FJHQD in the management of heart failure.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by Animal Ethics Committee of the Laboratory Animal Center, Zhejiang University.
Author contributions
Conception and design: ZY, YW, and XZ. Methodology and formal analysis: JL, YZ, and LZ. Writing of the manuscript: JL, ZY, and YZ. Supervision: ZY, YW, and XZ. Funding acquisition: ZY and XZ.

Funding
This work was financially supported by National Key R&D Program of China (No. 2018YFC1704502) and Hudong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (No. LHDMZ22H280001).

Acknowledgments
The authors are grateful for the support from ZIU PII-Tecan Joint Laboratory.

References
Abbate, A., Salloun, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., et al. (2008). Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117 (20), 2679–2683. doi:10.1161/circulationaha.107.780233
Bondia-Pons, I., Ryan, L., and Martínez, J. A. (2012). Oxidative stress and inflammation interactions in human obesity. J. Physiol. Biochem. 68 (4), 701–711. doi:10.1111/j.1748-1191.2011.03156.x
Bourdeau, D., and Beis, D. (2016). Zebra hypothesis revisited. J. Formos. Med. Assoc. 115 (3), 500–508. doi:10.1016/S0929-6646(15)30237-6
Gupta, A., Ghimire, G., and Hage, F. G. (2014). Guidelines in review: 2013 ACCF/AHA guideline for the management of heart failure. J. Nucl. Cardiol. 21 (2), 397–399. doi:10.1016/j.jncr.2013.03.041
D’Autillo, F., Nibali, L., Parati, M., Pastel, K., Suvan, J., and Donos, N. (2010). Oxidative stress, systemic inflammation, and severe periodontitis. J. Dent. Res. 89 (11), 1241–1246. doi:10.1177/0022034510375890
Giacomotto, J., and Segalat, L. (2010). High-throughput screening and small animal models, where are we? Br. J. Pharmacol. 160 (2), 204–216. doi:10.1111/j.1476-5381.2010.00725.x
Giordano, F. J. (2005). Oxidation, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115 (3), 500–508. doi:10.1172/jci24408
Gupta, A., Ghimire, G., and Hage, F. G. (2014). Guidelines in review: 2013 ACCF/AHA guideline for the management of heart failure. J. Nucl. Cardiol. 21 (2), 397–399. doi:10.1016/j.jncr.2013.03.041
Haleagrahara, N., Varkkey, J., and Chakravarthi, S. (2011). Cardioprotective effects of glycyrrhizic acid against isoproterenol-induced myocardial ischemia in rats. Int. J. Mol. Sci. 12 (10), 7100–7113. doi:10.3390/ijms12107100
Ho, Y. L., Lin, Y. H., Tsai, I. J., Hsieh, F. J., and Tsai, H. J. (2007). In vivo assessment of cardiac morphologic function in heart-sick green fluorescent zebras. J. Formos. Med. Assoc. 106 (5), 181–186. doi:10.1016/s0929-6646(09)60328-2
Huang, W. C., Liu, C. Y., Shen, S. C., Chen, L. C., Yeh, K. W., Liu, S. H., et al. (2019). Protective effects of licochalcone A improve airway hyper-responsiveness and oxidative stress in a mouse model of asthma. Zeitschrift für Naturforschung C 74 (6), 617. doi:10.1515/zfc-2018-06617
Hwa, B., Swa, B., Dza, B., Hxa, B., Hva, B., Msa, B., et al. (2021). A novel ion mobility separation-enabled and precursor ions list-included high-definition data-dependent acquisition (HDI-MS/MS) approach: Method development and its application to the comprehensive multicomponent characterization of Fangzi Huangqi Decoction. Arab. J. Chem. 14 (4), 103087. doi:10.1016/j.arabjc.2021.103087
Kwan, K. M., Fujimoto, E., Grabber, C., Mangum, B. D., Hardy, M. E., Campbell, D. S., et al. (2007). The To2kit: A multisite gateway-based construction kit for To2 transposon transgenesis constructs. Dev. Dyn. 236 (11), 3088–3099. doi:10.1002/dvdy.23134
Li, S., Liu, H., Li, Y., Qin, X., Li, M., Shang, J., et al. (2021). Shen-yuan-dan capsule attenuates verapamil-induced zebrafish heart failure and exerts antiapoptotic and anti-inflammatory effects via reactive oxygen species-induced NF-kB pathway. Front. Pharmacol. 12, 626515. doi:10.3389/fphar.2021.626515
Liu, B., Zhang, J. Z., Liu, W. H., Liu, N. N., Fu, X. Q., Kwan, H., et al. (2016). Calycosin inhibits oxidative stress-induced cardiomyocyte apoptosis via activating estrogen receptor-α/β. Biorg. Med. Chem. Lett. 26 (1), 181–185. doi:10.1016/j.bmcl.2015.11.005
Mann, D. L. (2015). Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ. Res. 116 (7), 1254–1268. doi:10.1161/circresaha.116.302317
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Bøhm, M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 42 (36), 3599–3726. doi:10.1093/eurheartj/ehab368
Merkle, S., Frantz, S., Schim, M. P., Bauersachs, J., Buttraga, M., Frost, R. J., et al. (2007). A role for caspase-1 in heart failure. Circ. Res. 100 (5), 645–653. doi:10.1161/01.res.000026203.55077.61
Ojha, S., Javed, H., Azimullah, S., Khair, S. B. A., and Haque, M. E. (2016). Glycyrrhizic acid attenuates neuroinflammation and oxidative stress in rotenone model of Parkinson’s disease. Neurotox. Res. 29 (2), 275–287. doi:10.1007/s12640-015-9579-2
Parrillo, J. E., Cunnion, R. E., Epstein, S. E., Parker, M. M., Saffredini, A. M., Brenner, M., et al. (1989). A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N. Engl. J. Med. 321 (16), 1061–1068. doi:10.1056/nejm198910193211601
Rossignol, P., Hernandez, A. F., Solomon, S. D., and Zannad, F. (2019). Heart failure drug treatment. Lancet 393 (10175), 1034–1044. doi:10.1016/s1474-5475(19)30755-7
Roth, G. A., Mensah, G. A., and Fuster, V. (2020). The global burden of cardiovascular diseases and risks: A compass for global action. J. Am. Coll. Cardiol. 76 (23), 2980–2981. doi:10.1016/j.jacc.2020.11.021

Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.999950/full#supplementary-material
Shi, X. J., Chen, R., Zhang, Y., Yan, J., Brand-Arzamendi, K., Liu, X. D., et al. (2018). Zebrasfish heart failure models: Opportunities and challenges. Amino Acids 50 (7), 787–798. doi:10.1007/s00726-018-2578-7

Shin, J. T., Pomerantsev, E. V., Mably, J. D., and MacRae, C. A. (2010). High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrasfish. Physiol. Genomics 42 (2), 300–309. doi:10.1152/physiogenomics.00206.2009

Sim, H. J., Yoon, S. H., Kim, M. S., Kim, B., Park, H. M., and Hong, J. (2015). Identification of alkaloid constituents from Funghci species using pH control liquid-liquid extraction and liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 29 (9), 837–854. doi:10.1002/rcm.7165

Singh, K., Zaw, A. M., Sekar, R., Palak, A., Allam, A. A., Ajarem, J., et al. (2016). Glycyrrhizic acid reduces heart rate and blood pressure by a dual mechanism. Molecules 21 (10), E1291. doi:10.3390/molecules21101291

Skudicky, D., Sliva, K., Bergemann, A., Candy, G., and Sareli, P. (2000). Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 84 (4), 438–439. doi:10.1136/heart.84.4.438

Sliva, K., Woodwiss, A., Candy, G., Badenhorst, D., Libhaber, C., Norton, G., et al. (2002). Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am. J. Cardiol. 90 (10), 1118–1122. doi:10.1016/s0002-9149(02)02779-0

Su, H. F., Shaker, S., Kuang, Y., Zhang, M., Ye, M., and Qiao, X. (2021). Phytochemistry and cardiovascular protective effects of huang-qi (Astragalus Radix). Med. Res. Rev. 41 (4), 1999–2038. doi:10.1185/med.21785

Takimoto, E., and Kass, D. A. (2007). Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49 (2), 241–248. doi:10.1161/01.HYP.0000254415.31662.47

Tsutsui, T., Kobayashi, S., Liu, Y. Y., and Kontani, H. (2003). Anti-hyperglycemic effect of fangchinoline isolated from Stephania tetrandra Radix in streptozotocin-diabetic mice. Biol. Pharm. Bull. 26 (3), 313–317. doi:10.1248/bpb.26.313

Tu, Y. Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17 (10), 1217–1220. doi:10.1038/nm.2471

van der Pol, A., van Gilst, W. H., Voors, A. A., and van der Meer, P. (2019). Treating oxidative stress in heart failure: Past, present and future. Eur. J. Heart Fail. 21 (4), 425–435. doi:10.1002/ejhf.1330

Wang, C., Chen, L., Xu, C., Shi, J., Chen, S., Tan, M., et al. (2020). A comprehensive review for phytochemical, pharmacological, and biosynthesis studies on Glycyrrhiza spp. Am. J. Chin. Med. 48 (1), 17–45. doi:10.1142/s0192415x20500020

Wang, Y. G., Zhou, J. M., Ma, Z. C., Li, H., Liang, Q. D., Tan, H. L., et al. (2012). Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: A possible mechanism for its hepatoprotective property against lithocholic acid-induced injury. Chem. Biol. Interact. 200 (1), 11–20. doi:10.1016/j.chbi.2012.08.023

Xiao, J., Song, N., Li, T., Pan, Y., Song, J., Chen, G., et al. (2018). Rapid characterization of TCM Qianjinteng by UPLC-QTOF-MS and its application in the evaluation of three species of Stephania. J. Pharm. Biomed. Anal. 156, 284–296. doi:10.1016/j.jpba.2018.04.044

Yang, Z., Li, J., Chen, X., Zhao, X., and Wang, Y. (2022). Deciphering bioactive compounds of complex natural products by tandem mass spectral molecular networking combined with an aggregation-induced emission based probe. J. Pharm. Anal. 12 (1), 129–135. doi:10.1016/j.jpha.2020.11.007

Yang, Z. Z., Li, Z. H., and Li, Z. (2018a). DPPH-HPLC-MS assisted rapid identification of endothelial protective substances from Xiao-Ke-An. J. Ethnopharmacol. 211, 188–196. doi:10.1016/j.jep.2017.07.016

Yang, Z. Z., Tang, H. T., Shao, Q., Bilia, A. K., Wang, Y., and Zhao, X. P. (2018b). Enrichment and purification of the bioactive flavonoids from flower of abelmoschus manihot (L.) medic using macroporous resins. Molecules 23 (10), 2649. doi:10.3390/molecules23102649

Zhang, H., Wang, Z., Feng, S. J., Xu, L., Shi, H. X., Chen, L. L., et al. (2015). PEDF improves cardiac function in rats with acute myocardial infarction via inhibiting vascular permeability and cardiomyocyte apoptosis. Int. J. Mol. Sci. 16 (3), 5618–5634. doi:10.3390/ijms16035618

Zhang, W. N., Yang, L., He, S. S., Qin, X. M., and Li, A. P. (2019). Metabolomics coupled with integrative pharmacology reveal the protective effect of FangjiHuangqi Decoction against adriamycin-induced rat nephropathy model. J. Pharm. Biomed. Anal. 174, 525–533. doi:10.1016/j.jpba.2019.03.023

Zhu, X. Y., Wu, S. Q., Guo, S. Y., Yang, H., Xia, B., Li, P., et al. (2018). A zebrasfish heart failure model for assessing therapeutic agents. Zebrfish 15 (3), 243–253. doi:10.1089/zeb.2017.1546